Sugi Predict

Sugi Predict / Compounds / SCHEMBL3227432

SCHEMBL3227432

SCHEMBL3227432

CCOC(=O)c1cc(C#N)c(Cl)nc1C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.71
▸ HSD17B10 Q99714 4/20 0.71
▸ L3MBTL1 Q9Y468 4/20 0.67
▸ GAA P10253 2/20 0.67
▸ ALDH1A1 P00352 9/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ TSHR P16473 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.52
▸ TDP1 Q9NUW8 3/20 0.52
▸ HPGD P15428 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ HTT P42858 1/20 0.48
▸ GPR55 Q9Y2T6 1/20 0.48
▸ POLB P06746 1/20 0.47
▸ P2RY12 Q9H244 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4874531 0.90 KDM4E (0.60) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL30782359 0.89 KDM4E (0.63) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL2225084 0.89 KDM4E (0.63) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL5316100 0.88 KDM4E (0.57) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4109638 0.86 L3MBTL1 (0.57) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4736378 0.85 KDM4E (0.53) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL2227187 0.85 GAA (0.69) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL3328003 0.85 KDM4E (0.55) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL16616673 0.84 KDM4E (0.72) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4875503 0.84 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12508268-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2025-12-30 — — US disclosed
EP-4651907-A1 DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME Adcentrx Therapeutics Inc. (US) 2025-11-26 — — EP disclosed
US-20240285641-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2024-08-29 — — US disclosed
US-20240254086-A1 (HETERO)ARYLAMIDE COMPOUND AND PEST CONTROL AGENT NIPPON SODA CO., LTD. (JP) 2024-08-01 — — US disclosed
WO-2024155761-A1 DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME ADCENTRX THERAPEUTICS INC. (US) 2024-07-25 — — WO disclosed
EP-4339187-A1 (HETERO)ARYLAMIDE COMPOUND AND PEST CONTROL AGENT Nippon Soda Co., Ltd. (JP) 2024-03-20 — — EP disclosed
CN-117618423-A Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy 奥克兰联合服务有限公司 2024-03-01 — — CN disclosed
CN-117599049-A Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy 奥克兰联合服务有限公司 2024-02-27 — — CN disclosed
CN-117279895-A (hetero) arylamide compound and pest control agent 日本曹达株式会社 2023-12-22 — — CN disclosed
US-11826316-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2023-11-28 — — US disclosed
WO-2008004941-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 — — WO disclosed
US-20080009523-A1 New Pyridine Analogues IV ASTRAZENECA AB (SE) 2008-01-10 — — US disclosed
WO-2008004942-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 — — WO disclosed
WO-2008004943-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 — — WO disclosed
WO-2008002247-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-03 — — WO disclosed
US-20070244088-A1 New Pyridine Analogues II ASTRAZENECA AB (SE) 2007-10-18 — — US disclosed
EP-1836189-A1 NOVEL PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2007-09-26 — — EP disclosed
WO-2006073361-A9 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2007-08-02 — — WO disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 — — WO disclosed
WO-2006073361-A1 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2006-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11826316-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy IDO1, TDO2, IDO2 KDM4E 768/4885HSD17B10 1530/4885L3MBTL1 3355/4885
US-20080009523-A1 New Pyridine Analogues IV P2RY12, P2RY4, P2RY11 KDM4E 2808/4885HSD17B10 3258/4885L3MBTL1 4802/4885
US-20240285641-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY IDO1, TDO2, IDO2 KDM4E 768/4885HSD17B10 1530/4885L3MBTL1 3355/4885
US-12508268-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy IDO1, IDO2, TDO2 KDM4E 1473/4885HSD17B10 1489/4885L3MBTL1 3879/4885
US-20240254086-A1 (HETERO)ARYLAMIDE COMPOUND AND PEST CONTROL AGENT H1-2, CTRL, BOLA2; BOLA2B KDM4E 2077/4885HSD17B10 1582/4885L3MBTL1 13/4885
US-20070244088-A1 New Pyridine Analogues II P2RY12, P2RY1, P2RY11 KDM4E 2897/4885HSD17B10 4199/4885L3MBTL1 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.